ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 62

Patient Perception of Disease Burden in Diffuse Cutaneous Systemic Sclerosis

Dinesh Khanna1, Yannick Allanore2, Christopher P. Denton3, Marco Matucci-Cerinic4, Janet E. Pope5, Barbara Hinzmann6, Siobhan Briody7, Janethe de Oliveira Pena8 and Oliver Distler9, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Immunogenetics, Cochin Institute, Paris, France, 3Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 4Department of Medicine, Division of Rheumatology, University of Florence, Florence, Italy, 5University of Western Ontario, London, ON, Canada, 6Bayer Pharma AG, Berlin, Germany, 7Blueprint Partnership, Manchester, United Kingdom, 8Bayer HealthCare Pharma, Whippany, NJ, 9Research of Systemic Autoimmune Diseases, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Cutaneous manifestations, patient outcomes and physical impairment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Diffuse cutaneous SSc (dcSSc) is associated with high morbidity and mortality, and reduced quality of life. Patient priorities are rarely discussed, with physicians traditionally focusing on organ involvement rather than skin changes. Using discursive approaches and ethnography, a unique, qualitative research methodology, we evaluated the impact of dcSSc symptoms on patients’ daily lives, and examined how disease burden shapes patient outlook.

Methods:

Patients were recruited via healthcare professionals (HCPs) or patient associations. In France, Italy, the UK and US, patients filmed daily short (~15-minute) video diaries about their lives over 7 days. On Days 1 and 7, patients took part in a moderator-led discussion of their experiences, and an observation session to understand the impact of living with dcSSc. In Germany and Spain, patients participated in 60-minute telephone interviews. Patients were also assigned tasks to encourage reflection on their feelings about dcSSc. Video footage and transcribed discussions were reviewed, and the data were categorized and assessed for themes, patterns, and indicators of emotion, ambivalence, and conflict.

Results:

Twenty-three patients (mean age 54; 83% women) were recruited. Of these, 17 made video diaries, and 6 took part in telephone interviews. The majority of video diaries and interviews took place in patients’ homes, and on average 5.25 hours of video footage were collected per patient.

The results of the study show that time to diagnosis may be delayed, as patients trivialize their symptoms and HCPs often attribute symptoms to other causes. Patients also have a poor understanding of their diagnosis, and information to aid understanding is rarely provided. DcSSc is associated with a high treatment burden; on average this patient sample received 10 tablets of prescribed drugs per day. Importantly, while patients were aware of the seriousness of organ involvement, they reported that skin changes, pain, and fatigue have a dominant effect on daily life, impairing their ability to perform routine tasks. Skin tightening in the lower limbs and feet lead to deformity and loss of mobility, while Raynaud’s phenomenon, calcinosis, and digital ulcers cause significant pain, as well as loss of function. Furthermore, skin tightening around the mouth impacts the ability to eat, and dental hygiene. Changes in esthetic appearance lead to embarrassment, loss of identity, withdrawal from social life, and depression. Patients experience dcSSc as a series of losses, including independence and self-esteem, and the unpredictability of the disease makes the patient journey and acceptance of the condition difficult. Moreover, patients tend to have small support networks and support services are not offered as part of standard care.

Conclusion:

Patients with dcSSc have high treatment and emotional burdens, with skin complications, pain, and fatigue profoundly impacting their daily lives. Patients place the most emphasis on these issues rather than the chance of organ involvement. There is an unmet need for patient information at the time of diagnosis and for emotional support services throughout their journey with dcSSc.


Disclosure: D. Khanna, Bristol-Myers Squibb, 2,EMD Serono, 2,Genentech and Biogen IDEC Inc., 2,Bayer, 5,Biogen Idec, 5,Cytori, 5,EMD Serono, 5,Forward, 5,Genentech and Biogen IDEC Inc., 5,Gilead, 5,Lycera, 5,Seattle Genetics, 5; Y. Allanore, Actelion, Bayer, Biogen, Bristol-Meyers Squibb, Inventiva, Medac, Pfizer, Roche/Genentech, Sanofi-Aventis, Servier, 2,Actelion, Bayer, Biogen, Bristol-Meyers Squibb, Inventiva, Medac, Pfizer, Roche/Genentech, Sanofi-Aventis, Servier, 5; C. P. Denton, GlaxoSmithKline, 2,Actelion Pharmaceuticals US, 5,GlaxoSmithKline, 5,Serono, 5,Inventiva, 5,CSL Behring, 2,Bayer, 5; M. Matucci-Cerinic, None; J. E. Pope, Bristol-Myers Squibb, 2; B. Hinzmann, Bayer Pharma AG, 3; S. Briody, None; J. de Oliveira Pena, Bayer HealthCare Pharma, 3; O. Distler, Consultancy relationships and/or has received research funding from Actelion, Pfizer, Ergonex, BMS, Sanofi-Aventis, United BioSource Corporation, Medac, Biovitrium, Boehringer Ingelheim, Bayer Pharma AG, Novartis, 4D Science and Active Biotech in the area, 2.

To cite this abstract in AMA style:

Khanna D, Allanore Y, Denton CP, Matucci-Cerinic M, Pope JE, Hinzmann B, Briody S, de Oliveira Pena J, Distler O. Patient Perception of Disease Burden in Diffuse Cutaneous Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/patient-perception-of-disease-burden-in-diffuse-cutaneous-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-perception-of-disease-burden-in-diffuse-cutaneous-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology